Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Inovas | Pharma | 56.5% | 100th pct | 110 |
| Krokus Pharma | Pharma | 34.1% | 83rd pct | 110 |
| Biopolusi | Pharma | 29.2% | 74th pct | 110 |
| Neoparmi | Pharma | -2.0% | 12th pct | 110 |
| Bioparmi | Pharma | -8.3% | 5th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Neoparmi | Bioparmi | Biopolusi | Inovas | Krokus Pharma |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 34.3% | 54.4% | 56.0% | 63.2% | 58.1% |
| EBITDA Margin | -2.0% | -8.3% | 29.2% | 56.5% | 34.1% |
| EBITDAR | 330 | -847 | 2,261 | 2,836 | 1,449 |
| EBITDAR Margin | 1.7% | -8.3% | 34.8% | 56.6% | 34.9% |
| EBIT Margin | -2.7% | -11.4% | 29.2% | 56.4% | 33.9% |
| Net Profit Margin | -3.1% | -12.6% | 23.6% | 54.8% | 30.6% |
| Operating Expense % of Sales | 36.2% | 62.8% | 26.8% | 6.7% | 24.0% |
| Returns | |||||
| Return on Assets (ROA) | -7.4% | -6.7% | 10.4% | 43.8% | 38.4% |
| Return on Equity (ROE) | -11.6% | -7.0% | 13.1% | 49.8% | 50.6% |
| ROIC [EBIT / Invested Capital] | -10.8% | -6.9% | 14.7% | 45.3% | 57.5% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.0% | 7.9% | 11.8% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.10x | 0.13x | 0.00x |
| Debt-to-EBITDA | N/A | N/A | 0.61x | 0.26x | 0.00x |
| Equity-to-Assets | 63.7% | 95.3% | 80.0% | 88.0% | 75.8% |
| Net Debt | -264 | -1,264 | 1,159 | 734 | -63 |
| Cash & Equivalents | 264 | 1,264 | 3 | 8 | 63 |
| Total Debt | N/A | N/A | 1,162 | 742 | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 1.91x | 0.28x | 8.26x | 5.31x | 4.06x |
| Quick Ratio | 1.91x | 0.28x | 8.26x | 5.31x | 4.06x |
| Cash Ratio | 0.09x | 1.42x | 0.00x | 0.01x | 0.08x |
| Total Current Assets | 5,533 | 251 | 14,600 | 3,456 | 3,253 |
| Total Current Liabilities | 2,894 | 888 | 1,767 | 650 | 802 |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Trade Receivables | 242 | 3,828 | 10,634 | 3,256 | 2,526 |
| Trade Payables | 1,581 | 888 | 1,314 | 8 | 726 |
| Net Working Capital | 2,639 | -637 | 12,833 | 2,805 | 2,451 |
| Net Working Capital % of Revenue | 13.8% | -6.3% | 197.8% | 56.0% | 59.0% |
| Trade Working Capital | -1,338 | 2,939 | 9,320 | 3,248 | 1,801 |
| Trade Working Capital % of Revenue | -7.0% | 29.0% | 143.6% | 64.8% | 43.3% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | 79.16x | 2.65x | 0.61x | 1.54x | 1.64x |
| Days Sales Outstanding (DSO) | 4.6 | 137.6 | 598.2 | 237.2 | 221.9 |
| Payables Turnover | 7.98x | 5.21x | 2.17x | 238.29x | 2.40x |
| Days Payable Outstanding (DPO) | 45.7 | 70.1 | 168.0 | 1.5 | 152.1 |
| Cash Conversion Cycle | -41.1 days | 67.5 days | 430.2 days | 235.7 days | 69.7 days |
| Asset Turnover | 2.41x | 0.53x | 0.44x | 0.80x | 1.25x |
| Cash flow & dividends | |||||
| Operating Cash Flow | -289 | 7,425 | 366 | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | -289 | 233 | -207 | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | 19.3% | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |